Acadia Pharmaceuticals Inc.

This study looked at the long-term safety of pimavanserin for treating irritability in children and teens (ages 5-17) with autism. It was an extension of an earlier 6-week study, lasting 52 weeks. The trial was terminated early, and results are not yet fully available.